Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with a primary brain tumour
1 finding from 1 review
Quality of life EORTC QLQ‐BN 20 · people with a primary brain tumour
1 finding from 1 review
Fatigue · people with a primary brain tumour
1 finding from 1 review
Fatigue –reduced motivation Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Cognition Symbol Digit Modalities Test (median (range)) · people with a primary brain tumour
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · people with a primary brain tumour
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review
Fatigue –reduced activity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Fatigue –severity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Adverse events ( · people with a primary brain tumour
It is very uncertain whether boele 2013: modafinil changes adverse events ( compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with a primary brain tumour
2 findings from 1 review
Cognition Trail Making Test A · people with a primary brain tumour
1 finding from 1 review
Cognition Trail Making Test B · people with a primary brain tumour
1 finding from 1 review
Progression‐free survival · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Overall survival (OS) · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin leads to higher haematological adverse event: Grade 3/4 anaemia compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in neurological adverse event: Grade 3/4 neuropathy, not otherwise… compared with tri‐weekly paclitaxel plus carboplatin (low certainty).
1 finding from 1 review
Intervention not reported
Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on prognosis…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
MS · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on prognosis…
1 finding from 1 review